Last update 01 Nov 2024

CD19 positive Mantle-Cell Lymphoma

Last update 01 Nov 2024

Basic Info

Synonyms-

Introduction-

Drugs associated with CD19 positive Mantle-Cell Lymphoma

IM19CAR-T(Beijing Immunochina Pharmaceuticals)

Target

CD19

Mechanism

CD19 modulators [+1]

Active Org.

Beijing Yimiao Medical Technology Co., Ltd. [+1]

Originator Org.

Beijing Imunopharm Technology Co., Ltd.Startup

Active Indication

Diffuse Large B-Cell Lymphoma [+9]

Inactive Indication

CD19 Expressing Malignancies [+1]

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with CD19 positive Mantle-Cell Lymphoma

CTR20213332 / RecruitingPhase 1/2

评估IM19 CAR-T细胞治疗复发或难治CD19阳性套细胞淋巴瘤患者的安全性和有效性的I/II期临床研究

[Translation] A phase I/II clinical study to evaluate the safety and efficacy of IM19 CAR-T cells in the treatment of patients with relapsed or refractory CD19-positive mantle cell lymphoma

主要目的：评估IM19 CAR-T细胞治疗复发或难治CD19 阳性套细胞淋巴瘤患者的安全性和疗效。次要目的：评估IM19 CAR-T细胞治疗复发或难治的CD19阳性套细胞淋巴瘤患者的除90天ORR外的其它疗效指标、药代动力学特征及免疫原性。

[Translation]

Primary objective: To evaluate the safety and efficacy of IM19 CAR-T cells in the treatment of patients with relapsed or refractory CD19-positive mantle cell lymphoma. Secondary objective: To evaluate other efficacy indicators, pharmacokinetic characteristics and immunogenicity of IM19 CAR-T cells in the treatment of patients with relapsed or refractory CD19-positive mantle cell lymphoma, except for 90-day ORR.

Start Date05 Jan 2022

Sponsor / Collaborator

Beijing Yimiao Medical Technology Co., Ltd.

100 Clinical Results associated with CD19 positive Mantle-Cell Lymphoma

100 Translational Medicine associated with CD19 positive Mantle-Cell Lymphoma

0 Patents (Medical) associated with CD19 positive Mantle-Cell Lymphoma

Literatures (Medical) associated with CD19 positive Mantle-Cell Lymphoma

PLOS ONEQ3 · CROSS-FIELD

Inhibition of Methyltransferases Accelerates Degradation of cFLIP and Sensitizes B-Cell Lymphoma Cells to TRAIL-Induced Apoptosis

Q3 · CROSS-FIELD

ArticleOA

Author: Braun, Frank K ; Wilkie-Grantham, Rachel ; Berkova, Zuzana ; Mathur, Rohit ; Sehgal, Lalit ; Chandra, Joya ; Samaniego, Felipe

Non-Hodgkin lymphomas (NHLs) are characterized by specific abnormalities that alter cell cycle regulation, DNA damage response, and apoptotic signaling. It is believed that cancer cells are particularly sensitive to cell death induced by tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL). However, many cancer cells show blocked TRAIL signaling due to up-regulated expression of anti-apoptotic factors, such as cFLIP. This hurdle to TRAIL's tumor cytotoxicity might be overcome by combining TRAIL-based therapy with drugs that reverse blockages of its apoptotic signaling. In this study, we investigated the impact of a pan-methyltransferase inhibitor (3-deazaneplanocin A, or DZNep) on TRAIL-induced apoptosis in aggressive B-cell NHLs: mantle cell, Burkitt, and diffuse large B-cell lymphomas. We characterized TRAIL apoptosis regulation and caspase activation in several NHL-derived cell lines pre-treated with DZNep. We found that DZNep increased cancer cell sensitivity to TRAIL signaling by promoting caspase-8 processing through accelerated cFLIP degradation. No change in cFLIP mRNA level indicated independence of promoter methylation alterations in methyltransferase activity induced by DZNep profoundly affected cFLIP mRNA stability and protein stability. This appears to be in part through increased levels of cFLIP-targeting microRNAs (miR-512-3p and miR-346). However, additional microRNAs and cFLIP-regulating mechanisms appear to be involved in DZNep-mediated enhanced response to extrinsic apoptotic stimuli. The capacity of DZNep to target cFLIP expression on multiple levels underscores DZNep's potential in TRAIL-based therapies for B-cell NHLs.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CD19 positive Mantle-Cell Lymphoma

Basic Info

Related

Analysis